new
phosphonomethoxi
ethoxi
pyrimidin
pmeodapi
phosphonomethoxi
ethyl
prodrug
prepar
promoieti
consist
carbonyloxymethyl
ester
pom
poc
alkoxyalkyl
ester
amino
acid
phosphoramid
andor
tyrosin
activ
prodrug
evalu
vitro
differ
viru
famili
none
synthes
prodrug
demonstr
activ
rna
virus
prove
activ
herpesvirus
includ
herp
simplex
viru
hsv
varicellazost
viru
vzv
human
cytomegaloviru
hcmv
bi
poc
bi
amino
acid
phosphoramid
prodrug
pmeodapi
inhibit
herpesviru
replic
lower
dose
parent
compound
although
select
hsv
vzv
slightli
improv
compar
pmeodapi
monooctadecyl
ester
emerg
potent
select
prodrug
hsv
vzv
hcmv
ec
mm
margin
antiherpesviru
activ
although
bi
hexadecylamidoltyrosyl
bi
pom
ester
also
potent
antiherpesviru
drug
less
select
monooctadecyl
ester
prodrug
acycl
nucleosid
phosphon
anp
compound
great
import
due
broad
spectrum
biolog
activ
especi
antivir
also
cytostat
immunomodulatori
antiparasit
becom
alreadi
clinic
avail
drug
cidofovir
treatment
human
cytomegaloviru
cmv
retin
aid
patient
adefovir
prodrug
form
adefovir
dipivoxil
treatment
hepat
b
hbv
tenofovir
either
tenofovir
disoproxil
fumar
newli
sinc
also
new
prodrug
form
tenofovir
alafenamid
taf
treatment
hiv
hbv
infect
hand
note
last
thirti
year
systemat
investig
anp
dozen
therapeut
attract
structur
synthes
never
advanc
stage
preclinicalclin
investig
structur
name
antiretrovir
purin
phosphonomethoxi
propyl
deriv
b
acycl
nucleosid
phosphon
base
moieti
c
phosphonomethoxi
alkoxi
openr
deriv
azadeaza
analogu
purin
phosphonomethoxi
ethyl
deriv
common
structur
attribut
anp
highli
polar
charact
caus
presenc
phosphon
acid
residu
respons
unfavour
pharmacolog
properti
low
cell
permeabl
low
oral
bioavail
overcom
problem
transform
free
acycl
nucleosid
phosphon
appropri
prodrug
often
solut
work
focu
two
pharmacolog
interest
anp
structur
phosphonomethoxi
ethoxi
pyrimidin
exampl
socal
openr
anp
group
deriv
name
phosphonomethoxi
ethyl
antivir
potenti
divers
prodrug
form
openr
anp
character
phosphonomethoxi
group
contain
aliphat
part
link
posit
via
oxygen
atom
evid
mimic
appropri
deriv
open
imidazol
ring
antivir
activ
essenti
ident
parent
compound
includ
enantiomer
specif
compound
pmeodapi
r
pmpodapi
pmeodapi
fig
effici
inhibitor
retrovirus
hbv
despit
number
antiretrovir
drug
current
avail
market
investig
new
structur
advis
sever
reason
risk
emerg
resist
none
known
drug
abl
erad
hiv
infect
complet
vaccin
yet
avail
earli
develop
new
drug
candid
necessari
due
longtim
process
last
vitro
laboratori
test
clinic
phase
final
approv
moreov
addit
reason
focu
openr
analog
pmeodapi
type
incorpor
effici
r
pmpa
tenofovir
revers
transcriptas
rt
mutant
effici
excis
r
pmpa
rt
contain
thymidin
analog
mutat
addit
pmeodapi
activ
retrovirus
also
dna
virus
especi
herpesvirus
often
affect
immunocompromis
patient
includ
hivaid
develop
anp
initi
laboratori
order
search
new
demethyl
epigenet
drug
similar
nucleosid
although
none
new
compound
fulfil
criterion
manag
find
new
class
antivir
agent
analogu
cidofovir
phosphonomethoxi
propyl
variou
ester
prodrug
deriv
cyclic
form
fig
compar
cidofovir
improv
select
prodrug
hexadecyloxyethyl
ester
cyclic
form
reveal
potent
antidna
viru
activ
also
highest
select
indic
ratio
activ
vs
toxic
order
thousand
eg
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
hcmv
disadvantag
complic
metabol
profil
bound
instabl
ring
alkalin
condit
includ
physiolog
ph
studi
stabil
variou
anp
found
much
better
stabil
anoth
deriv
ie
phosphonomethoxi
ethyl
despit
fact
antivir
activ
margin
free
phosphon
acid
form
select
compound
synthes
studi
prodrug
form
consid
fact
activ
mani
anp
increas
transform
appropri
prodrug
moreov
case
activ
enhanc
also
spectrum
activ
could
broaden
transform
prodrug
typic
exampl
antidna
viral
agent
phosphonomethoxi
propyl
adenin
hpmpa
whose
octadecyloxyethyl
ode
ester
potent
select
inhibitor
hepat
c
viru
replic
cidofovir
transform
hexadecyloxyethyl
ester
brincidofovir
whose
efficaci
also
enlarg
rna
viral
infect
includ
ebola
viru
fact
lipid
moieti
brincidofovir
found
requir
vitro
antivir
activ
ebola
viru
start
compound
phosphonomethoxi
ethoxi
pyrimidin
synthes
accord
procedur
describ
literatur
briefli
basecatalys
alkyl
diisopropyl
chloroethoxi
methylphosphon
gave
mixtur
appropri
oand
ndiisopropyl
phosphonoethoxi
methyl
deriv
nisom
separ
diisopropyl
ester
group
deprotect
bromotrimethylsilan
synthesi
prodrug
rather
complic
low
solubl
start
pmeodapi
final
manag
synthes
two
biodegrad
ester
prodrug
pivaloyloxymethyl
pom
isopropoxycarbonyl
oxymethyl
poc
ester
amino
acid
phosphoramid
prodrug
scheme
pivaloyloxymethyl
perform
reaction
start
phosphon
acid
chloromethyl
pival
use
n
n
base
reaction
proceed
slowli
give
mixtur
bi
pom
mono
pom
ester
chromatograph
separ
compound
isol
accept
yield
altern
reaction
condit
eg
reaction
dioxan
dbu
complet
fail
also
introduct
poc
group
differ
attempt
examin
variou
solvent
dbu
diisopropylethylamin
base
way
led
bi
poc
deriv
consist
transform
free
pmeodapi
tetrabutylammonium
salt
follow
heat
pocchlorid
dioxan
bi
amino
acid
phosphoramid
prodrug
prepar
direct
coupl
pmeodapi
ethyl
lalanin
pyridin
treatment
premix
solut
triphenylphosphin
dipyridyl
disulfid
aldrithiol
synthet
effort
obtain
phosphonomethoxi
ethyl
prodrug
target
carbonyloxymethyl
ester
pom
poc
alkoxyalkyl
ester
amino
acid
phosphoramid
tyrosin
base
prodrug
introduct
poc
pom
group
perform
action
appropri
alkyl
chlorid
n
n
dimethylformamid
ie
condit
describ
transform
adefovir
adefovir
dipivoxil
scheme
unfortun
contrari
adefovir
reactiv
solubl
much
lower
give
appropri
diester
modest
yield
accompani
format
monoest
pivaloyloxymethyl
monopom
deriv
even
obtain
main
reaction
product
amino
acid
phosphoramid
synthes
method
develop
jansa
start
phosphon
dialkyl
ester
diisopropyl
diethyl
ester
form
common
intermedi
synthes
anp
deprotect
bromotrimethylsilan
lead
bi
trimethylsilyl
ester
situ
hydrolys
final
phosphon
acid
principl
method
util
intermediari
bi
trimethylsilyl
ester
anp
directli
reaction
dithiodipyridin
triphenylphosphin
amino
acid
ester
obtain
bisamid
without
need
labori
procedur
isol
free
phosphon
acid
select
amino
acid
ester
direct
especi
diethyl
ester
lalanin
lphenylalanin
lead
prodrug
optim
pharmacokinet
profil
case
select
diethyl
ester
lphenylalanin
scheme
similarli
prepar
pom
poc
ester
obtain
desir
symmetr
bisamid
prodrug
also
monoamid
accompani
small
amount
monomethyl
ester
compound
form
probabl
chromatograph
separ
monoamid
prodrug
system
contain
high
percentag
methanol
anoth
type
prodrug
select
studi
includ
alkoxyalkylest
concept
prodrug
base
mimick
natur
occur
phospholipid
lysophosphatidylcholin
lpc
compound
use
lpc
natur
uptak
pathway
small
intestin
reach
target
tissu
achiev
oral
bioavail
import
compound
famili
hexadecyloxypropyl
ester
cidofovir
brincidofovir
current
phase
iii
clinic
trial
use
human
hcmv
adenoviru
infect
compound
also
investig
experiment
drug
smallpox
ebolaviru
infect
previou
studi
success
appli
alkoxyalkylest
approach
phosphonomethoxi
propyl
hpmpdap
within
search
new
bioavail
antipoxviru
agent
synthesi
mention
fig
synthesi
start
pmeazac
transform
first
tetrabutylammonium
salt
subsequ
treat
hexadecyloxypropyl
bromid
give
mixtur
diester
monoest
monoest
predomin
probabl
steric
reason
besid
small
amount
n
alkyl
product
isol
scheme
last
type
prodrug
includ
studi
amino
acid
ester
prodrug
esterif
phosphon
acid
residu
perform
via
free
hydroxyl
group
appropri
hydroxi
amino
acid
serin
valin
tyrosin
concept
origin
develop
mckenna
group
improv
oral
bioavail
hpmpc
hpmpa
pharmacokinet
studi
variou
amino
acid
dipeptid
prodrug
anp
final
reveal
tyrosin
singl
amino
acid
favor
promoieti
regard
prodrug
plasma
stabil
also
found
enzymat
stabil
tyrosin
promoieti
significantli
increas
replac
carboxyl
ester
alkyl
amid
group
highest
increas
bioavail
antivir
activ
observ
long
lipophil
alkyl
chain
incorpor
tyrosin
amid
group
comprehens
review
includ
synthesi
sar
studi
pharmacolog
tyrosin
nalkyl
amid
anp
prodrug
publish
recent
consid
find
decid
synthes
symmetr
bistyrosin
prodrug
whose
carboxyl
function
modifi
hexadecylamido
group
scheme
compound
prepar
via
alkyl
sodium
salt
whole
aliphat
moieti
ie
boc
protect
bi
hexadecylamidoltyrosyl
ester
phosphonomethoxi
ethyl
chlorid
boc
group
tyrosin
synthon
obtain
multistep
synthesi
diisopropyl
phosphonomethoxi
ethyl
chlorid
known
common
build
block
synthesi
divers
pme
deriv
isopropyl
group
remov
first
action
bromotrimethylsilan
follow
hydrolysi
intermediari
phosphon
acid
activ
reaction
oxalyl
chlorid
dmf
form
phosphorodichlorid
whose
reaction
bocprotect
hexadecyl
tyrosin
amid
presenc
triethylamin
form
diester
good
prepar
yield
tyrosin
amid
precursor
prepar
nbocltyrosin
standard
coupl
procedur
use
edc
nhydroxybenzotriazol
hobt
ch
cl
similarli
describ
alkyl
ltyrosin
amid
eg
octyl
octadecyl
synthes
compound
test
antivir
activ
human
cytomegaloviru
hcmv
varicellazost
viru
vzv
wild
type
thymidin
kinas
defici
tk
strain
herp
simplex
viru
wild
type
tk
strain
herp
simplex
viru
vaccinia
viru
vesicular
stomat
human
embryon
lung
hel
cell
coxsacki
viru
respiratori
syncyti
viru
human
cervix
carcinoma
hela
cell
viru
reoviru
sindbi
viru
coxsacki
viru
punta
toro
viru
green
monkey
kidney
vero
cell
felin
corona
viru
felin
kidney
crfk
cell
influenza
influenza
b
influenza
b
virus
canin
kidney
mdck
cell
none
synthes
compound
display
activ
rna
virus
sever
prove
activ
herpesvirus
tabl
among
synthes
pmeodapi
prodrug
bi
amino
acid
phosphoramid
prodrug
emerg
activ
one
hsv
vzv
hcmv
bi
poc
prodrug
activ
compound
hsv
vzv
prove
less
effect
hcmv
prodrug
hsv
vzv
activ
parent
drug
pmeodapi
gain
activ
hcmv
ec
mm
mm
respect
compound
versu
mm
compound
togeth
increas
antivir
potenc
augment
cc
cytostat
concentr
seen
compound
compar
pmeodapi
consequ
calcul
select
index
si
ratio
cc
ec
prodrug
hcmv
select
seen
si
howev
two
prodrug
select
inhibit
hsv
vzv
replic
si
respect
slightli
better
si
pmeodapi
ie
hsv
vzv
pivaloyloxymethyl
pmeodapi
led
synthesi
bi
pom
mono
pom
ester
strategi
result
improv
antiherpesviru
activ
thu
mono
pom
prodrug
potenc
select
virtual
ident
pmeodapi
bi
pom
prodrug
activ
pmeodapi
cytostat
result
decreas
select
compar
parent
drug
among
carbonyloxymethyl
ester
pom
poc
base
prodrug
bi
pom
compound
exhibit
improv
activ
compar
parent
margin
activ
herpesvirus
bi
pom
prodrug
inhibit
replic
hsv
vzv
hcmv
ec
rang
respect
amongst
alkoxyalkyl
ester
bi
octadecyloxytheyl
ester
n
alkyl
prodrug
depriv
antiherpesviru
properti
monooctadecyloxyethyl
ester
emerg
one
activ
prodrug
ec
tabl
antivir
cytotox
properti
synthes
compound
human
embryon
lung
hel
cell
compound
bi
pom
ester
prodrug
show
weak
activ
vaccinia
viru
ec
mm
although
select
observ
tabl
similarli
two
pmeodapi
prodrug
ie
bi
poc
ester
bi
amino
acid
phosphoramid
prodrug
demonstr
low
antivaccinia
viru
activ
without
select
success
synthes
carbonyloxymethyl
ester
pom
poc
alkoxyalkyl
ester
amino
acid
phosphoramid
tyrosin
base
prodrug
pmeodapi
andor
weak
margin
activ
herpesvirus
monooctadecyloxyethyl
ester
emerg
potent
select
inhibitor
herpesvirus
ie
hsv
vzv
hcmv
bi
hexadecylamidoltyrosyl
bi
pom
ester
also
potent
antiherpesviru
activ
less
select
monooctadecyloxyethyl
prodrug
bi
poc
bi
amino
acid
phosphoramid
prodrug
pmeodapi
prove
activ
parent
drug
hsv
vzv
hcmv
show
select
hsv
vzv
hcmv
unless
state
otherwis
solvent
evapor
kpa
compound
dri
pa
analyt
tlc
perform
silica
gel
f
plate
merck
kgaa
darmstadt
germani
chromatograph
system
describ
text
column
chromatographi
perform
silica
gel
lm
fluka
h
c
p
nmr
spectra
measur
bruker
avanc
iii
spectromet
equip
cryoprob
oper
mhz
h
mhz
c
p
nmr
spectra
measur
bruker
avanc
iii
spectromet
oper
ig
gener
number
scheme
assign
nmr
signal
decomposit
byproduct
follow
system
ethyl
acetateacetoneethanolwat
give
bi
pom
deriv
elut
column
methanol
afford
monopom
prodrug
yield
mg
colorless
syrup
methanol
solut
tetrabutylammonium
hydroxid
ml
ad
suspens
mg
mmol
absolut
meoh
ml
suspens
stir
vigor
treat
ultrason
bath
dissolut
clear
solut
evapor
residu
coevapor
dioxan
ml
dri
dioxan
ml
ad
follow
poc
chlorid
ml
mmol
mixtur
heat
h
reaction
cours
monitor
tlc
methanol
chloroform
mixtur
set
asid
room
temperatur
overnight
evapor
residu
partit
water
chloroform
ml
organ
layer
dri
na
evapor
residu
chromatograph
silica
gel
gradient
methanol
chloroform
yield
mg
white
amorph
solid
solut
consist
mg
mmol
ethyl
lalanin
g
mmol
triethylamin
ml
pyridin
ml
heat
min
solut
triphenylphosphin
g
mmol
aldrithiol
g
mmol
dissolv
pyridin
mmol
solut
ad
solut
whole
reaction
mixtur
heat
h
set
asid
room
temperatur
overnight
evapor
residu
coevapor
toluen
chromatograph
column
silica
gel
ml
start
system
methanol
chloroform
elut
triphenylphosphin
oxid
mercaptopyridin
follow
gradient
methanol
chloroform
crude
sirupi
product
g
still
contain
rest
ethyl
lalanin
purifi
chromatographi
silica
gel
system
ethyl
acetateacetoneethanolwat
mixtur
mg
mmol
n
g
mmol
poccl
ml
mmol
dmf
ml
stir
room
temperatur
day
mixtur
evapor
residu
coevapor
toluen
ml
chromatograph
silica
gel
column
start
ethyl
acet
elut
rest
poccl
follow
system
ethyl
acetateacetoneethanolwat
give
diester
r
f
monoest
r
f
yield
mg
white
solid
reaction
mg
mmol
ml
mmol
perform
condit
describ
previous
chromatographi
system
ethyl
acetateacetoneethanolwat
afford
bi
pom
ester
r
f
mono
pom
ester
r
f
bi
pivaloyloxymethyl
ester
phosphonomethoxi
ethyl
yield
mg
colorless
syrup
crystal
refriger
crude
product
mg
still
form
dicyclohexylmorpholinocarboxamidin
salt
appli
onto
column
dowex
na
form
ml
elut
water
uv
absorb
fraction
evapor
give
sodium
salt
yield
mg
white
solid
diisopropyl
ester
g
mmol
acetonitril
ml
stir
bromotrimethylsilan
ml
mmol
room
temperatur
h
mixtur
evapor
residu
coevapor
toluen
ml
mixtur
consist
diethyl
l
phenylalanin
hydrochlorid
g
mmol
pyridin
ml
triethylamin
ml
ad
argon
result
mixtur
heat
min
solut
ph
p
g
mmol
aldrithiol
g
mmol
pyridin
ml
ad
reaction
mixtur
heat
h
set
asid
room
temperatur
overnight
evapor
residu
coevapor
toluen
ml
appli
onto
column
silica
gel
subject
flash
chromatographi
start
chloroform
elut
ph
p
addit
elut
perform
gradient
meoh
chloroform
elut
ph
po
follow
pyridinethiol
bisamid
elut
subsequ
system
meoh
chloroform
product
contain
fraction
evapor
dri
vacuo
elut
bi
amid
column
elut
methanol
uv
absorb
eluat
concentr
adsorb
small
amount
silica
gel
ml
appli
onto
column
silica
gel
broad
short
column
ml
elut
system
ethyl
acetateacetoneethanolwat
afford
monoamid
prodrug
r
f
yield
mg
white
solid
solut
bu
n
oh
thf
ml
mmol
ad
stir
suspens
g
mmol
absolut
meoh
ml
min
result
solut
evapor
residu
coevapor
dmf
dri
dmf
ml
odebr
g
mmol
ad
reaction
mixtur
heat
h
mixtur
evapor
residu
partit
chloroform
water
organ
layer
dri
magnesium
sulphat
evapor
residu
chromatograph
column
silica
gel
ml
system
methanol
chcl
give
crude
product
r
f
r
f
compound
requir
purif
see
elut
column
methanol
afford
crude
monoest
purif
describ
cytomegaloviru
hcmv
strain
davi
vaccinia
viru
lederl
strain
respiratori
syncyti
viru
rsv
strain
long
vesicular
stomat
viru
vsv
coxsacki
parainfluenza
influenza
viru
subtyp
influenza
viru
b
sindbi
punta
toro
antivir
assay
base
inhibit
virusinduc
cytopath
plaqu
format
human
embryon
lung
hel
fibroblast
african
green
monkey
cell
vero
human
epitheli
cell
hela
madindarbi
canin
kidney
cell
mdck
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
incub
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
cytostat
activ
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cell
well
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
cc
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
select
index
compound
calcul
cc
ec
ratio
altern
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
